Archive · 28 Nov 2025
Indian Clinician Wins Prestigious Uveitis Gold Medal
Professor Vishali Gupta from PGIMER Chandigarh has won a very important award called the International Uveitis Study Group’s Gold Medal.
This is a big deal because she is the first person from India to win this award.
She has done important work in understanding and treating eye inflammation, especially related to tuberculosis.
She did all her training and research in India, which makes her achievement even more special.
She has also worked with doctors from all over the world to help patients with eye problems caused by tuberculosis.
She advises young researchers to be curious, persistent, and to share their work with others.
Professor Vishali Gupta is the first India-trained and India-based clinician to win the International Uveitis Study Group’s Gold Medal.
The award recognizes her significant contributions to the field of ocular inflammation and uveitis.
Gupta completed her medical training and research entirely in India, emphasizing the quality of Indian medical education and research.
She has made groundbreaking contributions, including identifying and naming TB serpiginous-like choroiditis and leading global collaborations on ocular tuberculosis.
Gupta advises young researchers to be persistent, innovative, and to make their work visible through presentations and publications.
- Who
- Professor Vishali Gupta, an India-trained and India-based clinician
- What
- Won the International Uveitis Study Group’s Gold Medal
- When
- Award to be presented in July 2026
- Where
- At the IUSG meeting in Tübingen, Germany
- Why
- For her significant contributions to the field of ocular inflammation and uveitis
- Recipient
- Professor Vishali Gupta
- Institution
- PGIMER Chandigarh
- Award
- International Uveitis Study Group’s Gold Medal
- Award Year
- 2026
- Award Location
- Tübingen, Germany
- Specialization
- Uveitis (ocular inflammation)
- Key Contribution
- TB serpiginous-like choroiditis identification
- Global Collaboration
- Collaborative Ocular TB Study (25 centers)